Is current HAE management forcing people to make trade‑offs?

Don’t miss what’s next in HAE

Life with HAE can be complicated and uncompromising.
Knowing how and when to take a medication shouldn’t be.

TRADE-OFFS WITH HAE INJECTIONS

FEAR OF NEEDLES

Needle phobia is common and may lead to delayed or avoided treatment1-3

FAMILY PLANNING

Treatment options should consider impact on personal choices in family planning4

REQUIRES TRAINING

Self-injection requires patient education and proper technique to ensure efficacy5-8

SIDE EFFECTS

May cause pain and/or a reaction at the injection site1,3,9

CUMBERSOME

May not be easily transportable1,3,10

Needle Fatigue

Long-term injectable regimens may be associated with diminished treatment adherence1,9

TRADE-OFFS WITH HAE ORALS

EFFICACY

On average, oral treatments may not provide injection‑like efficacy™12-14

MULTIPLE DOSES

On-demand treatment may require multiple doses to fully resolve an HAE attack15

SIDE EFFECTS

For prevention of attacks, currently available orals may have side effects that could lead people to discontinue therapy14,16-18

TRADE-OFFS WITH HAE INFUSIONS

TIME CONSUMING

Often require administration in a healthcare setting, delaying time to treatment19,20

HARD TO SELF‑ADMINISTER

Patients may have poor venous access and difficulty with administration20

MAY NEED OTHERS TO HELP

May require caregiver or professional support, limiting independence20

SIDE EFFECTS

May cause headaches, nausea, rash, and fever21

TRAVEL ISSUES

Equipment and storage needs can complicate treatment outside the home20

Red Balloon Yellow Balloon Blue Balloon Red Balloon Yellow Balloon Blue Balloon

People with HAE may not be living their life to the fullest if trade‑offs get in the way1,3,22

Click a balloon or the buttons below to better understand decisions people with HAE have to make.

Real person living with HAE.

Default HCP Image Convenience HCP Image Efficacy HCP Image Tolerability HCP Image
Efficacy
Tolerability
Convenience
Injections
Orals
Infusions

Today’s HAE management may be forcing people to choose among efficacy, tolerability, and convenience1,3,22

While efficacy is a key driver in HAE management, people also prioritize tolerability and convenience23,24

What barriers do your patients report most frequently in their HAE management?

What do your patients identify as their top priorities in managing HAE?

Are all your patients’ needs addressed with their current HAE management?

Is it possible to get injection-like efficacy with oral HAE treatment options?

Does management of HAE interfere with your patients’ personal and professional lives?

GET THE FACTS

HAE attacks may be triggered by injury, stress, or even excitement, but may also appear for unknown reasons25,26

The management of HAE includes two distinct therapeutic strategies: measures to prevent attacks and treatment for acute episodes12

Options that either inhibit production of bradykinin or compete with the bradykinin receptor are currently utilized27

Managing HAE is different from angioedema associated with histamine since antihistamines, corticosteroids, and epinephrine have little effect on HAE swelling28

Woman holding balloons representing Tolerability, Convenience, & Efficacy

Critical Role of Bradykinin

Woman holding balloons representing Tolerability, Convenience, & Efficacy

Living with HAE

References

  1. Radojicic C, et al. Allergy Asthma Proc. 2021;42(3):S4-S10.
  2. Riedl MA, et al. Allergy Asthma Proc. 2021;42:S17-S25.
  3. Betschel SD, et al. Allergy Asthma Clin Immun. 2024;20(43):1-8.
  4. Hsu FI, et al. Allergy Asthma Clin Immun. 2022;18(64):1-9.
  5. Haegarda [prescribing information]. CSL Behring GmbH. Accessed June 6, 2025. https://www.fda.gov/media/105611/download
  6. Takhzyro [prescribing information]. Dyax Corp. Accessed June 6, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761090s010lbl.pdf
  7. Firazyr [prescribing information]. Shire Human Genetic Therapies, Inc. Accessed June 6, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf
  8. Tuong L-AC, et al. Allergy Asthma Proc. 2014;35(3):250-254.
  9. Food and Drug Administration. The voice of the patient – Hereditary angioedema. Published May 2018. Accessed May 23, 2025. https://www.fda.gov/files/about%20fda/published/The-Voice-of-the-Patient—Hereditary-Angioedema.pdf
  10. Soteres DF, et al. Clin Case Rep. 2021;9(11):e05086.
  11. Data on file, Pharvaris.
  12. Betschel SD, et al. J Allergy Clin Immunol Pract. 2023;11(8):2315-2325.
  13. Geba D, et al. J Drug Assess. 2021;10(1):51-56.
  14. Covella B, et al. Future Pharmacol. 2024;4(1):41-53.
  15. Riedl MA, et al. N Engl J Med. 2024;391:32-43.
  16. Farkas H, et al. Clin Transl Allergy. 2021;11(4):e12035
  17. Wedner HJ, et al. J Allergy Clin Immunol Pract. 2021;9(6):2305-2314.e4.
  18. Zuraw B, et al. J Allergy Clin Immunol. 2021;148:164-172.
  19. Savarese L, et al. Allergy Asthma Proc. 2021;42(1):e1-e7.
  20. Riedl MA, et al. Ann Allergy Asthma Immunol. 2017;119(1):59-64.
  21. Cinryze [prescribing information]. Takeda Pharmaceuticals U.S.A., Inc. Accessed June 6, 2025. https://www.fda.gov/media/75907/download
  22. Lumry WR, et al. Allergy Asthma Proc. 2020;41(Suppl 1):S08-S13.
  23. Busse PJ, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.
  24. Riedl MA, et al. Allergy. 2020;75(11):2879-2887.
  25. Maurer M, et al. Allergy. 2022;77(7):1961-1990.
  26. Aygören-Pürsün E, et al. Orphanet J Rare Dis. 2014;9(99):1-9.
  27. Abdulkarim A, et al. Hereditary angioedema. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Accessed June 17, 2025.
  28. Lima H, et al. Front Allergy. 2023;10(4):1-5.